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a b s t r a c t
Background and purpose: Severe chronic kidney disease (CKD) is a risk factor for hemorrhagic events in
atrial ﬁbrillation (AF) patients on anticoagulation therapy. We postulated that even moderate CKD may
be a risk factor for hemorrhage and this recognitionwould improvepredictive capabilities of hemorrhagic
risk stratiﬁcation models in Japanese patients.
Methods and subjects: In this prospective study, 231 non-valvular AF patients were divided into three
groups according to estimated glomerular ﬁltration rate (eGFR) and followed-up for a median of 7.1
years. The clinical endpoint was a major hemorrhagic event (MHE). HAS-BLED score was calculated for
the cohort and the predictive capability of the original HAS-BLED score was comparedwith that in which
renal dysfunction was redeﬁned as eGFR<60mL/min/1.73m2.
Results: Forty-four MHEs occurred during follow-up. Compared to no/mild CKD group (≥60mL/min/
1.73m2), both moderate (30–59mL/min/1.73m2) and severe (<30mL/min/1.73m2) CKD groups had
higher MHE risks (log rank: both p<0.001). MHE risk of patients with moderate CKD was more than
threefold higher than the no/mild CKD group even after adjusting for other risk factors (hazard ratio 3.8,
95% conﬁdence interval 1.7–8.7). The C-statistic in receiver-operating curve analysis was numerically
but not signiﬁcantly superior in modiﬁed HAS-BLED score compared to original HAS-BLED score (0.67
and 0.64, respectively; p=0.55). However, using modiﬁed HAS-BLED score was associated with signif-
icant improvement of net reclassiﬁcation improvement (0.50, p=0.002) and integrated discrimination
improvement (0.033, p=0.043).
Conclusions: Moderate CKD contributes to the risk of future major hemorrhagic events in AF patients.
Modiﬁcation of HAS-BLED score by changing the deﬁnition of renal failuremarkedly improved predictive
capability.
4 Jap© 201
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Atrial ﬁbrillation (AF) is the most common type of arrhythmia
orldwide, with an estimated prevalence rate between 0.4% and
.0% depending on age; the prevalence rate is approximately 8% in
atientsolder than80years [1]. PatientswithAFhave increased risk
f stroke, andoral anticoagulation therapy (OAC) is a robustmethod
o prevent thrombotic events in AF patients. Overall, adjusted-dose
arfarin reduces the risk of stroke by two-thirds compared to no
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antithrombotic therapy, and the expected degree of absolute ben-
eﬁt is dependent on baseline risk [2,3]. However, warfarin is also
associated with increased risk of bleeding, and this risk must be
taken into consideration when using anticoagulants.
Over the past 10 years, the prevalence of chronic kidney dis-
ease (CKD) has increased and CKD is not a rare comorbidity in
AF patients. Indeed, one-third of all AF patients were reported to
have stage 3 or 4 CKD [4], with the rate being 13–27% for those on
hemodialysis [5–7]. The inﬂuence of CKD on AF patients has been
described in a number of studies indicating that renal dysfunction
increases not only the risk of thromboembolic events, but also the
risk of hemorrhagic events, especially for severe CKD [8–10]. There-
fore, recently derived risk stratiﬁcation tools for bleeding events
in AF patients have included “renal failure” as a risk factor for
hemorrhage. However, the deﬁnition of “renal failure” was vague
served.
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nd limited to severe renal failure or hemodialysis. For example,
n HAS-BLED score, patients were classiﬁed as renal failure if the
resence of chronic dialysis, renal transplantation, or serum cre-
tinine ≥200mol/L. However, this serum creatinine cutoff value
as little basis. Furthermore, in a recent study [11], the rational
ew Japanese coefﬁcient was reported as 0.808 for Modiﬁcation
f Diet in Renal Disease (MDRD) Study equation, and this means
9% lower GFR in Japanese thanwesterners at the same serum cre-
tinine level [12]. Taking these facts into consideration, whether
e can extrapolate this serum creatinine cutoff value as one of
he risk factors for hemorrhagic events in Japanese patients is of
nterest.
Therefore, we postulated that even moderate CKD deﬁned as
stimated glomerular ﬁltration rate (eGFR) calculated using the
DRDequationwith Japanesecoefﬁcientmaycontribute to the risk
f hemorrhagic events in AF patients with anticoagulation therapy,
nd moreover, that the inclusion of moderate CKD as a predic-
or of hemorrhagic events may improve the accuracy of existing
redictive models.
aterials and methods
tudy population
FromOctober to December 2005, outpatientswith non-valvular
F undergoingwarfarin therapy for ≥1 year were recruited for reg-
stration. A total of 231 patients agreed to participate in the study
nd were followed up at Kameda Medical Center. Non-valvular AF
as deﬁned as AF without prosthetic valve or rheumatic mitral
alve disease. At registration, a complete review was performed in
ll patients to determine the medical history, presence of comor-
idities, and medication. Exclusion criteria were the presence of
eart failure, cardiomyopathy, congenital heart disease, permanent
acemaker, uncontrolled pulmonary disease, thyroid dysfunction,
nd malignant disease.
Patients with systolic blood pressure over 140mmHg and/or
iastolic pressure over 90mmHg and those taking antihyperten-
ive agents were considered to have a history of hypertension.
ypercholesterolemia was deﬁned as serum total cholesterol level
220mg/dL or the requirement for treatment with lipid-lowering
gents. Patients were considered smokers if they were current
mokers.
Estimated GFR was calculated using the MDRD equation with
apanese coefﬁcient [11]. The left ventricular ejection fraction was
easured by two-dimensional echocardiography using the modi-
ed Simpson method.
This study was performed in compliance with the Declaration
f Helsinki and was approved by Kameda Medical Center Ethics
ommittees.
nticoagulation control
During follow-up, warfarin dose was adjusted according to rec-
mmendedprothrombin timeproposedby the JapaneseGuidelines
or Pharmacotherapy of Atrial Fibrillation; i.e., 2.0–3.0 in patients
70 years and 1.6–2.6 in patients ≥70 years [13]. The interval
etween measurements of international normalized ratio (INR) of
rothrombin timewasdecidedby the attendingphysician. Theper-
ent time in therapeutic range (%TTR) of INR is the proportion of the
stimated period in which the INR is within the target range rel-
tive to the total follow-up period. The %TTR was calculated with
he method ﬁrst described by Rosendaal et al. [14], which uses lin-
ar interpolation of consecutive INR values in each patient, and the
ercentageof INRvalues in the recommendedrangewascalculated.ology 64 (2014) 482–487 483
HAS-BLED score
The HAS-BLED score is a recent bleeding risk score recom-
mended for use in AF patients to estimate the risk of hemorrhagic
events [15]. This score assigns 1 point for the presence of each of
hypertension (uncontrolled systolic blood pressure >160mmHg),
abnormal renal and/or liver function, previous stroke, bleeding
history or predisposition, labile INR, elderly and concomitant
drugs and/or alcohol excess. According to the current guide-
lines, the HAS-BLED score of ≥3 indicates that the patient is at
a high risk of bleeding and requires caution and regular review
[16].
In this original score, “abnormal renal function” is deﬁned as the
presence of chronic dialysis or renal transplantation or creatinine
≥200mol/L (2.26mg/dL). We also calculated the modiﬁed HAS-
BLED score by changing the deﬁnition of abnormal renal function
to eGFR<60mL/min/1.73m2, and compared the predictive capa-
bility for hemorrhagic events. In this modiﬁed HAS-BLED score,
we excluded the factor “elderly” for assigning 1 point because
eGFR is calculated based on the patient’s age and inﬂuence of
age was assumed to be ampliﬁed if we included both “elderly”
and “eGFR”.
Outcome
The clinical endpoint was a major hemorrhagic event (MHE),
whichwas deﬁned according to the International Society of Throm-
bosis and Hemostasis criteria; i.e., clinically overt or associated
with a fall in the hemoglobin level of at least 2.0 g/L, resulting in
the need for transfusion of ≥2units of red blood cells, involving
a critical site (e.g., intracranial and retroperitoneal), or fatal [17].
Hemorrhages that occurred as a result of a surgical procedurewere
excluded.
Statistics
Baseline characteristics were analyzed for differences between
the groups by one-way analysis of variance (ANOVA) for contin-
uous variables and the chi-squared test or Fisher’s exact test for
categorical variables. Normal distributions were evaluated by the
Kolmogorov–Smirnov test, and non-normally distributed variables
were logarithmically transformed. Event-free survival curves were
constructed using the Kaplan–Meier survival method and were
compared using log rank statistics. We calculated hazard ratios
(HRs) derived from the Cox proportional hazard model to evalu-
ate the prognostic effects of each factor over the study period. All
baseline variables were included in the regression analyses. Mul-
tivariate analysis was performed using all variables with p<0.1 on
univariate analysis.
We performed receiver operator characteristic (ROC) curve
analysis and calculated the C-statistic of both original and mod-
iﬁed HAS-BLED scores; the results are presented with 95%
conﬁdence intervals (CIs). To examine the predictive powers
of these two models, we compared their C-statistic accord-
ing to the method of DeLong et al. [18], and continuous net
reclassiﬁcation improvement (NRI) and integrated discrimina-
tion improvement (IDI) with corresponding 95% CIs were also
calculated [19].The results are shown as means± SD for normally distributed
and with 25th–75th percentile range for non-normally distributed
continuous variables, numbers (%) for categorical data and HRs
with 95% CI. All statistical test values were two-sided, and p<0.05
was taken to indicate signiﬁcance in all analyses. Data analysis was
performed with R version 3.0.2.
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esults
atient characteristics
We registered and followed up 231 patients with non-valvular
F. None of the participants were missing, and all were com-
letely followed up at our hospital. Patients were divided into
hree groups according to eGFR (≥60mL/min/1.73m2, no/mild
KD; 30–59mL/min/1.73m2, moderate CKD; <30mL/min/1.73m2,
evere CKD). About half of the patients had no/mild CKD (48.1%),
9.0% had moderate CKD, and 12.9% had severe CKD. Fifteen of the
hirty patients with severe CKD were on dialysis. The clinical char-
cteristics of each group are shown in Table 1. Patients with severe
KD were older and more likely to have diabetes. There were no
igniﬁcant differences in bodymass index or antiplatelet drug pre-
cription rate. Average%TTRwas60.6 for all cohorts, and therewere
o signiﬁcant differences between the three CKD groups.
utcome
During themedian follow-up period of 7.1 years, 44MHEswere
bserved and 42 patients died due to non-hemorrhagic events. The
otal of 44MHEs consisted of intracranial hemorrhage (n=16), gas-
rointestinal bleeding (n=19), and others (n=9). The incidences of
HE for each CKD group were 7.2% for no/mild CKD, 25.6% for
oderate CKD, and 43.3% for severe CKD group (p<0.001). The
aplan–Meier curves shown in Fig. 1 illustrate the time to MHE
ccording to CKDgroupduring follow-up. Compared to the no/mild
KD group, both the moderate and severe CKD groups had higher
isks of MHE (log rank: both p<0.001). There was also a signiﬁcant
ifference in MHE-free survival rate between the moderate and
evere CKD groups (log rank=0.033). On univariate analysis, age,
ale gender, history of bleeding, non-steroidal anti-inﬂammatory
rug (NSAID), use and classiﬁcation of CKD groups were associ-
ted with higher risks of MHE. After adjusted multivariate Cox
egression analysis, including all variables with p<0.1 on univari-
te analysis, the presence of both moderate CKD (HR 3.87, 95% CI
able 1
aseline clinical characteristics of three CKD groups according to renal function.
Characteristics eGFR (mL/min/1.73m2)
≥60 30
CKD groups No/mild CKD Mo
Number of patients 111 90
Age (years) 68 (61.5–76) 74
Male (%) 70 (63.1) 57
BMI (kg/m2) 23.5±3.1 23
Serum creatinine (mg/dL) 0.8 (0.7–0.9) 1.1
eGFR (mL/min/1.73m2) 74.3±11.8 50
Comorbidities (%)
Hypertension 59 (53.2) 58
Coronary artery disease 16 (14.4) 14
Congestive heart failure 28 (25.2) 21
Dyslipidemia 32 (28.8) 26
Medication (%)
ACE-I 17 (15.3) 12
ARB 44 (39.6) 38
Calcium channel blocker 33 (29.7) 32
Beta blocker 19 (17.1) 25
Statin 22 (19.8) 26
Digoxin 21 (18.9) 25
Antiplatelet drugs 41 (36.9) 44
NSAIDs 3 (2.7) 4 (
Ejection fraction (%) 65.9 (58.4–71.9) 65
Left atrium diameter (cm) 49.9±7.8 49
BNP (pg/dL) 146.0 (98.9–233.5) 12
%TTR 56.9 (47.2–70.3) 65
CE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, b
stimated glomerular ﬁltration rate; NSAIDs, nonsteroidal anti-inﬂammatory drugs; %TTRiology 64 (2014) 482–487
1.71–8.76; p=0.001) and severe CKD (HR 8.56, 95% CI 3.50–21.20;
p<0.001) groupswere signiﬁcantly associatedwith increasedMHE
risk compared to the no/mild CKD group (Table 2).
Modiﬁcation of HAS-BLED score
We performed ROC analysis for MHE using both the original
HAS-BLED score andmodiﬁedHAS-BLED score, andC-statisticwere
compared (Fig. 2). The C-statistic in ROC analysis was numer-
ically but not signiﬁcantly superior in modiﬁed (0.67, 95% CI
0.57–0.75) compared to original HAS-BLED score (0.64, 95% CI
0.55–0.72) (p=0.55). However, using modiﬁed HAS-BLED score
was associated with signiﬁcant improvement of net reclassiﬁca-
tion improvement (0.50, p=0.002) and integrated discrimination
improvement (0.033, p=0.043).
Discussion
In this study, onlymoderate CKDwas an independent risk factor
forMHE even after adjustment for other risk factors. TheHAS-BLED
score signiﬁcantlypredicted futureMHEseven in Japanesepatients,
however, changing the deﬁnition of “renal failure” as one of the risk
factors for MHE could improve the predictive ability of HAS-BLED
score.
Recent studies have shown that even CKD stage 3 is an indepen-
dent predictor of stroke or thrombotic events in AF patients even
after adjusting for other comorbidities [4,20,21]. Indeed, including
renal impairment as a risk factor can improve the predictive ability
of the conventional risk stratiﬁcation model for thrombotic events
in AF patients [22].
On the other hand, in some reports, mild renal impairment was
also described as a risk factor for hemorrhage in patients treated
with anticoagulant therapy [23–25]. These observational studies
indicated that not only severe, but also moderate CKD could be
a risk factor for bleeding. However, the result was not adjusted
for age and other comorbidities [25]. Furthermore, as these studies
were phase 3 trials, some patients with complications would have
p value
–59 <30
derate CKD Severe CKD
30
(67–79) 74 (62.3–79) 0.476
(63.3) 24 (80.0) 0.208
.3±4.0 22.8±3.9 0.685
(0.9–1.1) 4.5 (2.3–6.2) <0.001
.2±6.9 12.7±7.9 <0.001
(64.4) 19 (63.3) 0.239
(15.6) 5 (16.7) 0.873
(23.3) 6 (20.0) 0.867
(28.9) 11 (36.7) 0.576
(13.3) 5 (16.7) 0.872
(42.2) 15 (50.0) 0.595
(35.6) 10 (33.3) 0.698
(27.8) 8 (26.7) 0.159
(28.9) 8 (26.7) 0.304
(27.8) 2 (6.7) 0.45
(48.9) 15 (50.0) 0.182
4.4) 3 (10.0) 0.21
.3 (56.0–69.9) 64.9 (59.1–70.7) 0.479
.1±7.1 52.6±10.1 0.122
8.3 (88.3–254.9) 128.5 (70.3–290.7) 0.476
.1 (53.1–72.3) 59.1 (50.3–71.3) 0.077
odymass index; BNP, brain natriuretic peptide; CKD, chronic kidney disease; eGFR,
, percent time in therapeutic range.
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Fig. 1. MHE-free survival curves stratiﬁed by CKD group (no/mild, moderate, and severe). CKD, chronic kidney disease; MHE, major hemorrhagic event; eGFR, estimated
glomerular ﬁltration rate.
Table 2
Cox regression analysis for major hemorrhagic events.
Variable Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age (per 1 year) 1.03 (0.99–1.07) 0.056 1.02 (0.99–1.06) 0.177
Male gender 2.08 (0.99–4.32) 0.051 1.94 (0.93–4.06) 0.079
History of bleeding 5.54 (0.75–40.8) 0.093 2.86 (0.38–21.5) 0.308
NSAIDs use 2.49 (0.90–6.96) 0.082 2.13 (0.74–6.17) 0.163
CKD groups
No/mild CKD Reference Reference
Moderate CKD 4.36 (1.95–9.77) <0.001 3.87 (1.71–8.76) 0.001
Severe CKD 10.43 (4.30–25.31)
HR, hazard ratio; CI, conﬁdence interval; CKD, chronic kidney disease; NSAIDs, nonsteroid
Fig. 2. Receiver-operating characteristic curves of the major hemorrhagic events
for original and modiﬁed HAS-BLED scores. C-statistic of modiﬁed HAS-BLED score
was numerically higher than that of the original score (0.64 vs 0.67, p=0.55).<0.001 8.56 (3.5–21.2) <0.001
al anti-inﬂammatory drugs.
been excluded, such as those with a history of bleeding or those at
high-risk of bleeding [23–25]. In contrast, our study included non-
valvular AF patients encountered in clinical practice. Our results
indicated that stage 3 CKD should be recognized as a major risk
factor for hemorrhagic events independent of other comorbidities
in a real-world clinical setting in Japanese patients.
One prospective cohort study evaluated the inﬂuence of renal
function on hemorrhagic events. This study indicated that stage 4
and 5 CKDwere independent predictors of hemorrhagic events, but
that stage 3CKDwasnot. In our long-term follow-up study (median
follow-up7.1 years),wehave shown that stage3CKDwas a risk fac-
tor for hemorrhagic events even after adjustment for age and some
other comorbidities. This means that the presence of CKD per se is
a risk factor for hemorrhage in AF patients treated with warfarin.
This discordance may be explained by the differences in TTR, base-
line disease, and ethnic factors. In the previous study, less than half
of the patients had AF, and the others had a history of deep venous
thrombosis, pulmonary thromboembolism, or stroke. In contrast,
our cohort included only AF patients. Furthermore, we included
only Japanese AF patients. Ethnic differences in the incidence of
intracranial hemorrhage were described previously in multieth-
nic non-rheumatic AF patients who were prescribed warfarin. The
results of this study indicated that Asians were at four times the
risk for intra-cranial hemorrhage compared to whites even after
adjusting for other comorbidities [26].
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Three risk scores have been validated for assessing hem-
rrhagic risks in AF patients, i.e., ATRIA [27], HAS-BLED, and
EMORR2HAGES scores [15,28]. Although all of these risk scor-
ng systems include “renal failure” as one of the risk factors, only
evere renal impairment is included in these models. Speciﬁcally,
TRIA score andHEMORR2HAGES score consider renal impairment
s a risk factor only in patients with eGFR<30mL/min/1.73m2 or
n those dependent on dialysis, and the HAS-BLED score considers
enal impairment as a risk factor in patients on dialysis, with renal
ransplantation or creatinine level ≥200mol/L. Here, we demon-
trated the validity of considering even stage 3 CKD as a risk factor
or hemorrhagic events, and the ability of HAS-BLED score for pre-
icting future hemorrhagic events was signiﬁcantly improved by
hanging the cutoff for renal failure to eGFR<60mL/min/1.73m2.
We investigated the clinical signiﬁcance of this modiﬁcation of
enal failure only in the HAS-BLED model, and it will be neces-
ary to investigate the validity of this modiﬁcation in other risk
tratiﬁcation models. However, some recent studies indicated that
he HAS-BLED score has better predictive value than other scores
29,30]. Given these results and its simplicity, the HAS-BLED score
s more clinically applicable than the other scores.
From a clinical perspective, the results of this study will con-
ribute to more accurate identiﬁcation of patients at high risk
or major hemorrhage events in Japanese patients. Reclassify-
ng the patients correctly from low risk to high risk will lead to
fforts to correct the potentially reversible risk factors for bleed-
ng (e.g., uncontrolled blood pressure, inappropriate use of aspirin
r NSAIDs, and uncontrolled INR) and substantially reduce the
ajor hemorrhagic events in this population. Therefore, improve-
ent of the predictive value of this score by making a simple
hange to the deﬁnition of renal failure has marked clinical
mplications.
imitations
Although the whole cohort in this study was followed up for a
ong time, we included only a small number of AF patients. Second,
e lost three patients due to sudden death from unknown etiol-
gy, and these deaths may have been due to bleeding. However,
his number would not critically inﬂuence the main result of our
tudy. Third, the follow-up interval was at the physician’s discre-
ion because thiswas a purely observational study. Fourth, we used
GFR of baseline and did not follow-up the changes of eGFR. This
ight be a confounder for evaluating the inﬂuence of renal function
n hemorrhagic events. Finally, we determined the modiﬁed HAS-
LED score but the external validation of this score for predicting
uture hemorrhagic events remains to be elucidated in other data
ets.
onclusions
Evenmoderate CKD could contribute to futureMHE in Japanese
atients with AF. Although the HAS-BLED score predicted future
HE in Japanese patients, changing the cutoff value for renal fail-
re in HAS-BLED score from serum creatinine ≥200mol/L to
GFR<60mL/min/1.73m2 improved predictive ability of this scor-
ng system in clinical practice. As this change is easy and has
arked clinical implications, the inﬂuence of these two scores for
etermining prognosis should be investigated in future large-scale
rials.onﬂict of interest statement
The authors declare that they have no conﬂict of interest.
[
[iology 64 (2014) 482–487
Authors’ contributions
M.S. wrote the paper; Y.M. designed the study and analyzed
data; R.N. interpreted the data; A.M. gave technical support and
conceptual advice; and Y.H. drafted the manuscript and revised it
critically for important intellectual content.
References
[1] Fuster V, Ryden LE, CannomDS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL,
Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S,
Smith Jr SC, et al. ACC/AHA/ESC2006guidelines for themanagement of patients
with atrial ﬁbrillation – executive summary: a report of theAmericanCollege of
Cardiology/American Heart Association Task Force on Practice Guidelines and
the European Society of Cardiology Committee for Practice Guidelines (Writing
Committee to Revise the 2001Guidelines for theManagement of PatientsWith
Atrial Fibrillation). J Am Coll Cardiol 2006;48:854–906.
[2] McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial ﬁbrilla-
tion: review of the evidence for the role of pharmacologic therapy, electrical
cardioversion, and echocardiography. Ann Intern Med 2003;139:1018–33.
[3] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to pre-
vent stroke in patientswho have nonvalvular atrial ﬁbrillation. Ann InternMed
2007;146:857–67.
[4] Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L,
Singer DE. Impact of proteinuria and glomerular ﬁltration rate on risk of throm-
boembolism in atrial ﬁbrillation: the anticoagulation and risk factors in atrial
ﬁbrillation (ATRIA) study. Circulation 2009;119:1363–9.
[5] Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C,
Guzman M, Gil JM, Borrego MJ, Perez V. Inﬂuence of atrial ﬁbrillation on the
morbido-mortality of patients on hemodialysis. Am Heart J 2000;140:886–90.
[6] Bozbas H, Atar I, Yildirir A, Ozgul A, Uyar M, Ozdemir N, Muderrisoglu H, Ozin
B. Prevalence and predictors of arrhythmia in end stage renal disease patients
on hemodialysis. Ren Fail 2007;29:331–9.
[7] Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, Acquistapace I,
Stella A, Bonforte G, DeVecchi A, DeCristofaro V, Buccianti G, Vincenti A. Preva-
lence of atrial ﬁbrillation and associated factors in a population of long-term
hemodialysis patients. Am J Kidney Dis 2005;46:897–902.
[8] Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT,
AllonM. Kidney function inﬂuences warfarin responsiveness and hemorrhagic
complications. J Am Soc Nephrol 2009;20:912–21.
[9] Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodial-
ysis patients: a systematic review of bleeding rates. Am J Kidney Dis
2007;50:433–40.
10] McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for
outpatients treated with warfarin. J Gen Intern Med 1998;13:311–6.
11] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino
Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum
creatinine in Japan. Am J Kidney Dis 2009;53:982–92.
12] Rule AD, Teo BW. GFR estimation in Japan and China: what accounts for the
difference? Am J Kidney Dis 2009;53:932–5.
13] Ogawa S, Aizawa Y, Atarashi H, Kamakura S, Koretsune Y, Kumagai K,
Mitamura H, Okumura K, Sugi K, Yamashita T, Yasaka M, Hiejima K, Kodama I,
Ohe T, Yano K. Guidelines for pharmacotherapy of atrial ﬁbrillation (JCS 2008):
digest version. Circ J 2010;74:2479–500.
14] Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to deter-
mine the optimal intensity of oral anticoagulant therapy. Thromb Haemost
1993;69:236–9.
15] Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-
friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients
with atrial ﬁbrillation: the Euro Heart Survey. Chest 2010;138:1093–100.
16] Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alﬁeri O, Angelini A, Atar
D, Colonna P, et al. Guidelines for the management of atrial ﬁbrillation: the
Task Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC). Eur Heart J 2010;31:2369–429.
17] Schulman S, Kearon C. Deﬁnition of major bleeding in clinical investigations of
antihemostaticmedicinal products in non-surgical patients. J ThrombHaemost
2005;3:692–4.
18] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two
or more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics 1988;44:837–45.
19] PencinaMJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassiﬁcation
improvement calculations to measure usefulness of new biomarkers. Stat Med
2011;30:11–21.
20] Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, Taguchi Y,
Dougu N, Nozawa T, Tanaka K, Inoue H. Chronic kidney disease and CHADS(2)
score independently predict cardiovascular events and mortality in patients
with nonvalvular atrial ﬁbrillation. Am J Cardiol 2011;107:912–6.21] Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial ﬁbrilla-
tion patients with moderate chronic kidney disease. Clin J Am Soc Nephrol
2011;6:2599–604.
22] Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR,
Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC,
f Cardi
[
[
[
[
[
[
[M. Suzuki et al. / Journal o
Nessel CC, Fox KA, et al. Renal dysfunction as a predictor of stroke and systemic
embolism in patients with nonvalvular atrial ﬁbrillation: validation of the
R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct
factor Xa inhibition Compared with vitamin K antagonism for prevention of
stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation
and Risk factors In Atrial ﬁbrillation) study cohorts. Circulation 2013;127:
224–32.
23] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,
Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD,
Ezekowitz JA, Flaker G, et al. Apixaban versus warfarin in patients with atrial
ﬁbrillation. N Engl J Med 2011;365:981–92.
24] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J,
Diaz R, et al. Dabigatran versus warfarin in patients with atrial ﬁbrillation. N
Engl J Med 2009;361:1139–51.25] Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF,
Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke
and systemic embolism with rivaroxaban compared with warfarin in patients
with non-valvular atrial ﬁbrillation andmoderate renal impairment. Eur Heart
J 2011;32:2387–94.
[ology 64 (2014) 482–487 487
26] Shen AY, Yao JF, Brar SS, JorgensenMB, ChenW. Racial/ethnic differences in the
risk of intracranial hemorrhage amongpatientswith atrial ﬁbrillation. J AmColl
Cardiol 2007;50:309–15.
27] Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N,
Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: the
ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll
Cardiol 2011;58:395–401.
28] Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW,
Radford MJ. Clinical classiﬁcation schemes for predicting hemorrhage:
results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J
2006;151:713–9.
29] Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the
HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in
patients with atrial ﬁbrillation undergoing anticoagulation: the AMADEUS
(evaluating the use of SR 34006 compared to warfarin or acenocoumarol in
patients with atrial ﬁbrillation) study. J Am Coll Cardiol 2012;60:861–7.
30] Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M,
Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores
for the risk of serious bleeding in a “real-world” population with atrial ﬁbrilla-
tion receiving anticoagulant therapy. Chest 2013;143:179–84.
